Molecular imaging in drug discovery and development

Nature Reviews Drug Discovery

Volumn 2, Issue 2, 2003, Pages 123-131

  Rudin, Markus ^a   Weissleder, Ralph ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; BOMBESIN RECEPTOR; CARBON 11; CASPASE 3; CATHEPSIN B; CATHEPSIN D; CATHEPSIN K; DRUG; DYSPROSIUM; FLUCONAZOLE; FLUORINE 18; FLUOROCHROME; GADOLINIUM; IMATINIB; INDIUM 111; INTERLEUKIN 1BETA CONVERTING ENZYME; IODINE; IRON OXIDE; LUCIFERIN; METALLOPROTEINASE INHIBITOR; NEUROLEPTIC AGENT; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; OXYGEN 15; PHOTOPROTEIN; PRINOMASTAT; PROTEINASE; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M; THROMBIN; UNINDEXED DRUG; ZIPRASIDONE;

BIOLUMINESCENCE; COMPUTER ASSISTED TOMOGRAPHY; CONFOCAL MICROSCOPY; COST; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RESEARCH; DRUG TARGETING; FLUORESCENCE ANALYSIS; HUMAN; ISOTOPE LABELING; MOLECULAR PROBE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ULTRASOUND; ANIMAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; PHARMACOKINETICS; PHARMACOLOGY; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION;

ANIMALS; DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; PHARMACOKINETICS; PHARMACOLOGY; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0037313516     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1007     Document Type: Review

References (79)

1. Weissleder, R. Scaling down imaging: molecular mapping of cancer in mice. Nature Rev. Cancer 2, 11-18 (2002).
2. Weissleder, R. & Ntziachristos, V. Shedding light onto live molecular targets. Nature Med. 9, 123-128 (2003).
3. Rudin, M. et al. In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives. NMR Biomed. 12, 69-97 (1999).
4. Beckmann, N., Mueggler, T., Allegrini, P. R., Laurent, D. & Rudin, M. From anatomy to the target: contributions of magnetic resonance imaging to preclinical pharmaceutical research. Anat. Rec. 265, 85-100 (2001).
5. Jain, R. K., Munn, L. L. & Fukumura, D. Dissecting tumour pathophysiology using intravital microscopy. Nature Rev. Cancer 2, 266-276 (2002).
6. Phelps, M. E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc. Natl Acad. Sci. USA 97, 9226-9233 (2000).
7. Fischman, A. J., Alpert, N. M. & Rubin, R. H. Pharmacokinetic imaging: a noninvasive method for determining drug distribution and action. Clin. Pharmacokinet. 41, 581-602 (2002).
8. Reese, T., Bochelen, D., Sauter, A., Beckmann, N. & Rudin, M. Magnetic resonance angiography of the rat cerebrovascular system without the use of contrast agents. NMR Biomed. 12, 189-196 (1999).
9. Villringer, A. et al. Dynamic imaging with lanthanide chelates in normal brain: contrast due to magnetic susceptibility effects. Magn. Reson. Med. 6, 164-174 (1988).
10. Roussel, S. A., van Bruggen, N., King, M. D. & Gadian, D. G. Identification of collaterally perfused areas following focal cerebral ischemia in the rat by comparison of gradient echo and diffusion-weighted MRI. J. Cereb. Blood Flow Metab. 15, 578-586 (1995).
11. Moseley, M., Wendland, M. & Kucharczyk, J. Magnetic resonance imaging of diffusion and perfusion. Top. Magn. Reson. Imag. 3, 50-67 (1991).
12. Sauter, A. & Rudin, M. Calcium antagonists reduce the extent of infarction in rat middle cerebral artery occlusion model as determined by quantitative magnetic resonance imaging. Stroke 17, 1228-1234 (1986).
13. Rausch, M., Baumann, D., Neubacher, U. & Rudin, M. In vivo visualization of phagocytotic cells in rat brains after transient ischemia by USPIO. NMR Biomed. 15, 278-283 (2002).
14. Sauter, A. et al. Recovery of function in cytoprotected cerebral cortex in rat stroke model assessed by functional MRI. Magn. Reson. Med. 47, 759-765 (2002).
15. Cristofanilli, M., Charnsangavej, C. & Hortobagyi, G. N. Angiogenesis modulation in cancer research: novel clinical approaches. Nature Rev Drug Discov. 1, 415-426 (2002).
16. Tatum, J. L. & Hoffman, J. M. Role of imaging in clinical trials of antiangiogenesis therapy in oncology. Acad. Radiol. 7, 798-799 (2000).
17. Bhujwalla, Z. M. et al. The physiological environment in cancer vascularization, invasion and metastasis. Novartis Found. Symp. 240, 23-38; discussion 38-45, 152-153 (2001).
18. Lewin, M. et al. In vivo assessment of vascular endothelial growth factor-induced angiogenesis. Int. J. Cancer 83, 798-802 (1999).
19. Petrovsky, A., Weissleder, W., Shalinsky, D., Hu-Lowe, D. & Bogdanov, A. Non-invasive magnetic resonance imaging (MRI) of vascular parameters affected by VEGF-receptor tyrosine kinase inhibition in a human xenograft model. Proc. Am. Assoc. Cancer Res. 43, 1081 (2002).
20. Peterfy, C. G. Magnetic resonance imaging of rheumatoid arthritis: the evolution of clinical applications through clinical trials. Semin. Arthritis Rheum. 30, 375-396 (2001).
21. McConnell, M. V. et al. MRI of rabbit atherosclerosis in response to dietary cholesterol lowering. Arterioscler. Thromb. Vasc. Biol. 19, 1956-1959 (1999).
22. Chinnaiyan, A. M. et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl Acad. Sci. USA 97, 1754-1759 (2000).
23. Jennings, D. et al. Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia 4, 255-262 (2002).
24. Evelhoch, J. L. et al. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2, 152-165 (2000).
25. Cherry, S. R. Fundamentals of positron emission tomography and applications in preclinical drug development. J. Clin. Pharmacol. 41, 482-491 (2001).
26. Del Guerra, A. & Belcari, N. Advances in animal PET scanners. Q. J. Nucl. Med. 46, 35-47 (2002).
27. Green, L. A. et al. Noninvasive methods for quantitating blood time-activity curves from mouse PET images obtained with fluorine-18-fluorodeoxyglucose. J. Nucl. Med. 39, 729-734 (1998).
28. Chatziioannou, A., Tai, Y. C., Doshi, N. & Cherry, S. R. Detector development for microPET II: a 1 microl resolution PET scanner for small animal imaging. Phys. Med. Biol. 46, 2890-2910 (2001).
29. Brady, F. et al. Radiolabelled tracers and anticancer drugs for assessment of therapeutic efficacy using PET. Curr. Pharm. Des. 7, 1863-1892 (2001).
30. Halldin, C., Gulyas, B. & Farde, L. PET studies with carbon-11 radioligands in neuropsychopharmacological drug development. Curr. Pharm. Des. 7, 1907-1929 (2001).
31. 18F fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography Antimicrob. Agents Chemother. 40, 659-664 (1996).
32. Fischman, A. J. et al. Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. J. Pharmacol. Exp. Ther. 279, 939-947 (1996).
33. Aboagye, E. O. et al. Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. Br. J. Cancer 86, 1052-1056 (2002).
34. Gibson, R. E. et al. Non-invasive radiotracer imaging as a tool for drug development. Curr. Pharm. Des. 6, 973-989 (2000).
35. 18F-labeled fluconazole in healthy human subjects by positron emission tomography. Antimicrob. Agents Chemother. 37, 1270-1277 (1993).
36. Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nature Rev Drug Discov. 1, 493-502 (2002).
37. Coussens, L. M., Fingleton, B. & Matrisian, L. M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392 (2002).
38. Warner, R. R. & O'Dorisio T. M. Radiolabeled peptides in diagnosis and tumor imaging: clinical overview. Semin. Nucl. Med. 32, 79-83 (2002).
39. Becker, A. et al. Receptor targeted optical imaging of tumors with near-infrared fluorescent ligands. Nature Biotechnol. 19, 327-331 (2001).
40. Bugaj, J. E., Achilefu, S., Dorshow, R. B. & Rajagopalan, R. Novel fluorescent contrast agents for optical imaging of in vivo tumors based on a receptor-targeted dye-peptide conjugate platform. J. Biomed. Opt. 6, 122-133 (2001).
41. Tung, C. H., Lin, Y., Moon, W. K. & Weissleder, R. A receptor-targeted near-infrared fluorescence probe for in vivo tumor imaging. Chembiochem 3, 784-786 (2002).
42. Weissleder, R. et al. In vivo magnetic resonance imaging of transgene expression. Nature Med. 6, 351-355 (2000).
43. Hogemann, D., Ntziachristos, V., Josephson, L. & Weissleder, R. High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. Bioconjug. Chem. 13, 116-121 (2002).
44. Sipkins, D. A. et al. Detection of tumor angiogenesis in vivo by αVβ3-targeted magnetic resonance imaging. Nature Med. 4, 623-626 (1998).
45. Burns, H. D. et al. Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development. Curr. Opin. Chem. Biol. 3, 388-394 (1999).
46. Hartvig, P., Bergstrom, M., Antoni, G. & Langstrom, B. Positron emission tomography and brain monoamine neurotransmission - entries for study of drug interactions. Curr. Pharm. Des. 8, 1417-1434 (2002).
47. Fowler, J. S. et al. Positron emission tomography studies of dopamine-enhancing drugs. J. Clin. Pharmacol. (Suppl.) 13-16 (1999).
48. Hietala, J. Ligand-receptor interactions as studied by PET: implications for drug development. Ann. Med. 31, 438-443 (1999).
49. Laakso, A. & Hietala, J. PET studies of brain monoamine transporters. Curr. Pharm. Des. 6, 1611-1623 (2000).
50. Passchier, J. & van Waarde, A. Visualisation of serotonin-1A (5-HT1A) receptors in the central nervous system. Eur. J. Nucl. Med. 28, 113-129 (2001).
51. Pilowsky, L. S. Probing targets for antipsychotic drug action with PET and SPET receptor imaging. Nucl. Med. Commun. 22, 829-833 (2001).
52. Volkow, N. D., Ding, Y. S., Fowler, J. S. & Gatley, S. J. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol. Psychiatry 49, 211-220 (2001).
53. Waarde, A. Measuring receptor occupancy with PET. Curr. Pharm. Des. 6, 1593-1610 (2000).
54. 11C WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 24, 209-229 (2001).
55. Louie, A. Y. et al. In vivo visualization of gene expression using magnetic resonance imaging. Nature Biotechnol. 18, 321-325 (2000).
56. Perez, J. M., Josephson, L., O'Loughlin, T., Hogemann, D. & Weissleder, R. Magnetic relaxation switches capable of sensing molecular interactions. Nature Biotechnol. 20, 816-820 (2002).
57. Bremer, C., Tung, C. H. & Weissleder, R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nature Med. 7, 743-748 (2001).
58. Mahmood, U., Tung, C. H., Tang, Y. & Weissleder, R. Feasibility of in vivo multichannel optical imaging of gene expression: experimental study in mice. Radiology 224, 446-451 (2002).
59. Lewin, M. et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nature Biotechnol. 18, 410-414 (2000).
60. Sharma, V., Luker, G. D. & Piwnica-Worms, D. Molecular imaging of gene expression and protein function in vivo with PET and SPECT. J. Magn. Reson. Imaging 16, 336-351 (2002).
61. Zhao, M., Kircher, M.F., Josephson, L. & Weissleder, R. Differential conjugation of tat peptide to superparamagnetic nanoparticles and its effect on cellular uptake. Bioconjug. Chem. 13, 840-844 (2002).
62. Tjuvajev, J. G. et al. Imaging the expression of transfected genes in vivo. Cancer Res. 55, 6126-6132 (1995).
63. Gambhir, S. S. et al. Imaging adenoviral-directed reporter gene expression in living animals with positron emission tomography. Proc. Natl Acad. Sci. USA 96, 2333-2338 (1999).
64. Li, X., Zhang, S., Zhao, P., Kovacs, Z. & Sherry, A. D. Synthesis and NMR studies of new DOTP-like lanthanide(III) complexes containing a hydrophobic substituent on one phosphonate side arm. Inorg. Chem. 40, 6572-6579 (2001).
65. Bornhop, D. J. et al. Fluorescent tissue site-selective lanthanide chelate, Tb-PCTMB for enhanced imaging of cancer. Anal. Chem. 71, 2607-2615 (1999).
66. Tromberg, B. J. et al. Non-invasive in vivo characterization of breast tumors using photon migration spectroscopy. Neoplasia 2, 26-40 (2000).
67. Chance, B. Near-infrared (NIR) optical spectroscopy characterizes breast tissue hormonal and age status. Acad. Radiol. 8, 209-210 (2001).
68. Hanlon, E. B. et al. Prospects for in vivo Raman spectroscopy. Phys. Med. Biol. 45, R1-R59 (2000).
69. Brown, E. B. et al. In vivo measurement of gene expression angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nature Med. 7, 864-868 (2001).
70. Ntziachristos, V., Tung, C. H., Bremer, C. & Weissleder, R. Fluorescence molecular tomography resolves protease activity in vivo. Nature Med. 8, 757-760 (2002).
71. Marten, K. et al. Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology 122, 406-414 (2002).
72. Ito, S. et al. Detection of human gastric cancer in resected specimens using a novel infrared fluorescent anti-human carcinoembryonic antigen antibody with an infrared fluorescence endoscope in vitro. Endoscopy 33, 849-853 (2001).
73. Zonios, G., Bykowski, J. & Kollias, N. Skin melanin, hemoglobin, and light scattering properties can be quantitatively assessed in vivo using diffuse reflectance spectroscopy. J. Invest. Dermatol. 117, 1452-1457 (2001).
74. Kuroiwa, T., Kajimoto, Y. & Ohta, T. Development and clinical application of near-infrared surgical microscope: preliminary report. Minim. Invasive. Neurosurg. 44, 240-242 (2001).
75. Ntziachristos, V., Ripoll, J. & Weissleder, R. Would near-infrared fluorescence signals propagate through large human organs for clinical studies? Opt. Lett. 27, 333-335 (2002).
76. Contag, C. H. et al. Visualizing gene expression in living mammals using a bioluminescent reporter. Photochemistry & Photobiology 66, 523-531 (1997).
77. Hastings, J. W. Chemistries and colors of bioluminescent reactions: a review. Gene 173, 5-11 (1996).
78. Bhaumik, S. & Gambhir, S. S. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc. Natl Acad. Sci. USA 99, 377-382 (2002).
79. Nicholson, J. K., Connelly, J., Lindon, J. C. & Holmes, E. Metabonomics: a platform for studying drug toxicity and gene function. Nature Rev. Drug Discov. 1, 153-161 (2002).